Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) - Total Assets
Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) holds total assets worth €457.93 Million EUR (≈ $535.36 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Eckert & Ziegler Strahlen- und Medizinte to assess the company's total reinvestment commitment from operating cash flow.
Eckert & Ziegler Strahlen- und Medizintechnik AG - Total Assets Trend (2013–2025)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's total assets have evolved over time, based on quarterly financial data. Explore EUZ strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Eckert & Ziegler Strahlen- und Medizintechnik AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Eckert & Ziegler Strahlen- und Medizintechnik AG's total assets of €457.93 Million consist of 54.2% current assets and 45.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 28.1% |
| Accounts Receivable | €44.96 Million | 9.8% |
| Inventory | €45.97 Million | 10.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €11.11 Million | 2.4% |
| Goodwill | €34.58 Million | 7.6% |
Asset Composition Trend (2013–2025)
This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Eckert & Ziegler Strahlen- und Medizinte market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eckert & Ziegler Strahlen- und Medizintechnik AG's current assets represent 54.2% of total assets in 2025, an increase from 40.7% in 2013.
- Cash Position: Cash and equivalents constituted 28.1% of total assets in 2025, up from 16.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 28.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 10.0% of total assets.
Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Total Assets
Key competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Medacta Group SA
SW:MOVE
|
Switzerland | CHF860.76 Million |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Xiangyu Medical Co. Ltd. A
SHG:688626
|
China | CN¥3.27 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
Eckert & Ziegler Strahlen- und Medizintechnik AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.45 | 3.12 | 3.85 |
| Quick Ratio | 2.81 | 2.51 | 3.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €176.18 Million | €153.15 Million | €132.57 Million |
Eckert & Ziegler Strahlen- und Medizintechnik AG - Advanced Valuation Insights
This section examines the relationship between Eckert & Ziegler Strahlen- und Medizintechnik AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.66 |
| Latest Market Cap to Assets Ratio | 1.98 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | €457.93 Million |
| Market Capitalization | $905.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values Eckert & Ziegler Strahlen- und Medizintechnik AG's assets above their book value (1.98x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Eckert & Ziegler Strahlen- und Medizintechnik AG's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2025)
The table below shows the annual total assets of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €457.93 Million ≈ $535.36 Million |
+3.51% |
| 2024-12-31 | €442.40 Million ≈ $517.21 Million |
+0.69% |
| 2023-12-31 | €439.36 Million ≈ $513.66 Million |
+5.40% |
| 2022-12-31 | €416.84 Million ≈ $487.33 Million |
+19.87% |
| 2021-12-31 | €347.73 Million ≈ $406.53 Million |
+19.08% |
| 2020-12-31 | €292.00 Million ≈ $341.38 Million |
+6.48% |
| 2019-12-31 | €274.24 Million ≈ $320.61 Million |
+19.73% |
| 2018-12-31 | €229.05 Million ≈ $267.78 Million |
+5.56% |
| 2017-12-31 | €216.99 Million ≈ $253.68 Million |
+8.78% |
| 2016-12-31 | €199.47 Million ≈ $233.20 Million |
+1.42% |
| 2015-12-31 | €196.68 Million ≈ $229.93 Million |
+4.99% |
| 2014-12-31 | €187.33 Million ≈ $219.01 Million |
+5.00% |
| 2013-12-31 | €178.41 Million ≈ $208.58 Million |
-- |
About Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more